SCHMC

Changes in Treatment After Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography in Patients With Prostate Cancer: A Retrospective Case Series Study

Metadata Downloads
Abstract
Purpose
The use of gallium-68 prostate-specific membrane antigen-11 positron emission tomography/computed tomography (Ga-68 PSMA-11 PET/CT) is becoming increasingly common among men with prostate cancer (PCa). However, it remains uncertain which patients will derive the most benefit, and there is a scarcity of real-world data regarding its impact on altering treatment plans. This study investigated which patients would most benefit from Ga-68 PSMA-11 PET/CT, focusing on detection rates and changes in treatment strategies, drawing from a single-center experience.
Materials and Methods
In total, 230 men with PCa who underwent Ga-68 PSMA-11 PET/CT between November 2021 and August 2022 were included in this retrospective study. The patients were classified into 5 groups based on their disease status: group 1, further work-up for high-risk localized PCa; group 2, de novo metastatic PCa; group 3, biochemical recurrence after definitive treatment; group 4, castration-resistant PCa; group 5, others. The positivity rate, positive lesions, predictive value of lymph node metastases, comparison with conventional images, and treatment changes after Ga-68 PSMA-11 PET/CT were analyzed in each group.
Results
Of the 230 patients, 40 (17.4%), 20 (8.7%), 77 (33.5%), 76 (33.0%), and 17 (7.4%) were classified into groups 1-5, respectively. Ga-68 PSMA-11 PET/CT showed lesions in 74.8% of patients, and the optimal cutoff value for PSA was 1.99 ng/mL. Lesions not observed on conventional imaging were found in 62 patients (33.2%). In 38 patients (13.5%), treatment was changed due to Ga-68 PSMA-11 PET/CT.
Conclusions
These real-world data suggest that Ga-68 PSMA-11 PET/CT may be clinically useful for various disease conditions, as substantial stage migration and subsequent treatment changes occur in men with PCa. However, the prognostic impact of this modality remains unclear; thus, a well-designed prospective study is needed to address this issue.
All Author(s)
Si Hyun Kim ; Chang Wook Jeong ; Minh-Tung Do ; Jang Hee Han ; Seung-Hwan Jeong ; Hyeong Dong Yuk ; Ja Hyeon Ku ; Hyeon Hoe Kim ; Gi Jeong Cheon ; Cheol Kwak
Intsitutional Author(s)
김시현
Issued Date
2024
Type
Article
Keyword
Positron emission tomographyComputed tomographyGallium-68 prostate-specific membrane antigen-11Prostatic neoplasmsLymph nodeCancer staging
Publisher
대한비뇨기종양학회
대한전립선학회
The Korean Urological Oncology Society
The Korean Prostate Society
ISSN
2951-603X ; 2982-7043
Citation Title
Journal of Urologic Oncology
Citation Volume
22
Citation Number
2
Citation Start Page
157
Citation End Page
165
Language(ISO)
eng
DOI
10.22465/juo.244800380019
URI
http://schca-ir.schmc.ac.kr/handle/2022.oak/4653
Appears in Collections:
비뇨의학과 > 1. Journal Papers
Authorize & License
  • Authorize공개
Files in This Item:

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.